Cabaletta Bio, Inc

(NASDAQ:CABA)

Latest On Cabaletta Bio, Inc (CABA):

Date/Time Type Description Signal Details
2023-05-18 16:00 ESTNewsCabaletta Bio up 1%, prices $87M offeringN/A
2023-05-18 02:29 ESTNewsCabaletta Bio commences underwritten public offering of sharesN/A
2023-05-16 23:33 ESTNewsCabaletta Bio jumps 16% as FDA clears trial for myositis candidateN/A
2023-05-11 15:27 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.02N/A
2023-05-01 18:20 ESTNewsCabaletta's potential lupus drug CABA-201 gets FDA fast track tagN/A
2023-04-28 03:16 ESTNewsCabaletta Bio: Speculative Biotech With OpportunityN/A
2023-03-31 16:02 ESTNewsCabaletta CAR T cell therapy for lupus gets FDA nod to enter trialN/A
2023-03-31 16:02 ESTNews4 stocks to watch on Friday: Amazon, Kraft Heinz, and moreN/A
2023-03-16 13:19 ESTNewsCabaletta Bio GAAP EPS of -$0.52 misses by $0.08N/A
2023-01-27 17:59 ESTNewsCabaletta rises as Morgan Stanley upgrades citing new CAR-T assetN/A
2023-01-25 12:46 ESTNewsCabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)N/A
2022-12-08 20:30 ESTNewsCabaletta Bio dips on announcing $35M offeringN/A
2022-11-10 11:40 ESTNewsCabaletta Bio GAAP EPS of -$0.39 beats by $0.09N/A
2022-08-30 16:03 ESTNewsCabaletta downgraded at Morgan Stanley on upcoming data for lead assetN/A
2022-08-11 21:46 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.05N/A
2022-05-18 20:14 ESTNewsCabaletta Bio updates Phase 1 interim data for lead assetN/A
2022-05-12 11:04 ESTNewsCabaletta Bio GAAP EPS of -$0.45N/A
2022-03-18 09:46 ESTNewsCabaletta Bio GAAP EPS of -$0.49 beats by $0.11N/A
2021-12-14 08:41 ESTNewsCabaletta Bio tanks 34% on cell therapy data in early-stage study for pemphigus vulgarisN/A
2021-11-01 14:01 ESTNewsCabaletta Bio EPS beats by $0.05N/A
2021-11-01 14:01 ESTNewsCabaletta rises as skin diseases drug shown to be safe in early data of phase 1 trialN/A
2021-08-19 00:00 ESTNewsCabaletta Bio reports results from DesCAARTes trial in patients with pemphigus vulgarisN/A
2021-08-05 20:25 ESTNewsCabaletta Bio EPS beats by $0.03N/A
2021-03-18 15:25 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $22.25.Buy
2021-03-18 07:46 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 17:01 ESTNewsCabaletta Bio EPS misses by $0.04N/A
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$2.18 is estimated for the 2022 year.Sell
2021-01-20 12:58 ESTNewsCabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young BiotechN/A
2021-01-11 10:22 ESTAnalyst RatingThe Analyst Target Price has increased from $20 to $20.33.Buy
2021-01-09 03:37 ESTNewsChardan Capital initiates Cabaletta Bio with Buy ratingN/A
2020-12-10 06:47 ESTNewsDosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorderN/A
2020-12-04 06:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 15:51 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.67 to $20.Neutral
2020-11-17 07:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 23:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 07:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 09:52 ESTNewsCabaletta Bio EPS beats by $0.08N/A
2020-11-11 09:52 ESTNewsCabaletta Bio +5% on Q3 results, pipeline updateN/A
2020-11-11 06:54 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-10-15 08:02 ESTNewsCabaletta Bio (CABA) Investor Presentation - SlideshowN/A
2020-10-14 11:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.5 to $21.67.Neutral
2020-10-08 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 03:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 23:40 ESTFinancialsCompany financials have been released.Neutral

About Cabaletta Bio, Inc (CABA):

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Quotes by TradingView

See Advanced Chart

General

  • Name Cabaletta Bio, Inc
  • Symbol CABA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 31
  • Fiscal Year EndDecember
  • IPO Date2019-10-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.cabalettabio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.23
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.13
  • Next Year EPS Estimate -$2.45
  • Next Quarter EPS Estimate -$0.42
  • Return on Assets -17%
  • Return on Equity -27%
  • Earnings Per Share -$0.94
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 276.24 million
  • Analyst Target Price $22.25
View More

Share Statistics

  • Shares Outstanding 24.06 million
  • Shares Float 7.91 million
  • % Held by Insiders 523%
  • % Held by Institutions 67.4%
  • Shares Short 1.63 million
  • Shares Short Prior Month 1.61 million
  • Short Ratio 15.52
  • Short % of Float 8%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $16.38
  • 52 Week Low $6.07
  • 50 Day Moving Average 11.96
  • 200 Day Moving Average 12.4
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cabaletta Bio, Inc (CABA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cabaletta Bio, Inc (CABA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.40-$0.36-11.11%
2020-09-302020-11-10$N/A-$0.36-$0.4418.18%
2020-06-302020-08-06$N/A-$0.35-$0.3910.26%
2020-03-312020-05-12$N/A-$0.33-$0.23-43.48%
2019-12-312020-03-30$N/A-$0.33-$0.4729.79%
2019-09-302019-12-05$N/A-$1.21-$2.2646.46%

Cabaletta Bio, Inc (CABA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Cabaletta Bio, Inc (CABA) Chart:

Cabaletta Bio, Inc (CABA) News:

Below you will find a list of latest news for Cabaletta Bio, Inc (CABA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cabaletta Bio, Inc (CABA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-03-210.50CALL0 0418.65TRUE00
2025-03-2111.2CALL15 0285.15TRUE1.20
2025-03-211.50CALL0 0160.39TRUE00
2025-03-2120.35CALL1 854131.04TRUE-0.05-0.13
2025-03-212.50.2CALL2 222143.52FALSE-0.1-0.33
2025-03-2150.05CALL0 98223.21FALSE00
2025-03-217.50.1CALL0 50FALSE00
2025-03-210.50PUT0 0776.36FALSE00
2025-03-2110.05PUT1 0220.99FALSE0.050
2025-03-211.50.1PUT0 35220.84FALSE00
2025-03-2120.2PUT1 27107.14FALSE0.20
2025-03-212.50.57PUT11 463129.17TRUE-0.03-0.05
2025-03-2150PUT0 0174.59TRUE00
2025-03-217.55.3PUT0 1686.02TRUE00
2025-04-170.50CALL0 0299.38TRUE00
2025-04-1710CALL0 0184.21TRUE00
2025-04-171.50CALL0 0113.73TRUE00
2025-04-1720CALL0 085.24TRUE00
2025-04-172.50CALL0 0141.24FALSE00
2025-04-1750CALL0 00FALSE00
2025-04-177.50CALL0 00FALSE00
2025-04-170.50PUT0 01005.42FALSE00
2025-04-1710PUT0 0269.72FALSE00
2025-04-171.50PUT0 0148.62FALSE00
2025-04-1720PUT0 0150.98FALSE00
2025-04-172.50PUT0 0150.33TRUE00
2025-04-1750PUT0 0236.97TRUE00
2025-04-177.50PUT0 0230.69TRUE00
2025-05-160.52CALL0 2241.35TRUE00
2025-05-1610CALL0 0354.21TRUE00
2025-05-161.50.93CALL0 3128.67TRUE00
2025-05-1620CALL0 0127.85TRUE00
2025-05-162.50.5CALL1 414132.69FALSE0.10.25
2025-05-1650.15CALL40 1247157.69FALSE-0.04-0.21
2025-05-167.50.15CALL0 385188.9FALSE00
2025-05-16100.07CALL15 452189.36FALSE0.020.4
2025-05-160.50PUT0 0631.05FALSE00
2025-05-1610.05PUT0 60163.63FALSE00
2025-05-161.50.2PUT0 10148.03FALSE00
2025-05-1620.37PUT0 190.31FALSE00
2025-05-162.51.1PUT1 67212.22TRUE1.10
2025-05-1652.88PUT0 399148.34TRUE00
2025-05-167.50PUT0 0192.18TRUE00
2025-05-16105.71PUT0 0257.47TRUE00
2025-08-150.50CALL0 0164.06TRUE00
2025-08-1511.48CALL5 0217.46TRUE1.480
2025-08-151.51.15CALL0 1111.98TRUE00
2025-08-1521.25CALL0 2130.52TRUE00
2025-08-152.51.05CALL0 195125.99FALSE00
2025-08-1550.35CALL15 1265148.45FALSE0.050.17
2025-08-157.50.3CALL0 291136.99FALSE00
2025-08-150.50.05PUT0 10443.05FALSE00
2025-08-1510.2PUT0 6144.73FALSE00
2025-08-151.50.35PUT15 0128.93FALSE0.350
2025-08-1520.75PUT0 3140.88FALSE00
2025-08-152.51.05PUT1 17141.19TRUE1.050
2025-08-1552.9PUT0 219141.29TRUE00
2025-08-157.55.7PUT0 2127.15TRUE00
2025-11-210.52.3CALL0 34331.25TRUE00
2025-11-2111.45CALL0 4171.35TRUE00
2025-11-211.51.25CALL0 13176.44TRUE00
2025-11-2121.3CALL2 1145.03TRUE1.30
2025-11-212.51CALL0 1244144.79FALSE00
2025-11-2150.45CALL6 534132.46FALSE00
2025-11-217.50.35CALL0 846142.57FALSE00
2025-11-210.50PUT0 0358.98FALSE00
2025-11-2110PUT0 0162.09FALSE00
2025-11-211.50PUT0 0145.36FALSE00
2025-11-2120.82PUT0 20144.26FALSE00
2025-11-212.51PUT0 306145.88TRUE00
2025-11-2153.6PUT0 33139.58TRUE00
2025-11-217.55.5PUT0 58139.08TRUE00

Latest CABA Trades:

Date Shares Price
Jun 13, 2022 7:37 PM EST1$1.08
Jun 13, 2022 7:37 PM EST6$1.08
Jun 13, 2022 7:51 PM EST7$1.06
Jun 13, 2022 7:57 PM EST7$1.06
Jun 13, 2022 7:58 PM EST7$1.055

Cabaletta Bio, Inc (CABA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025941/0000899243-19-025941-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025942/0000899243-19-025942-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025943/0000899243-19-025943-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025946/0000899243-19-025946-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025947/0000899243-19-025947-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026016/0000899243-19-026016-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026017/0000899243-19-026017-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026018/0000899243-19-026018-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026020/0000899243-19-026020-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026345/0000899243-19-026345-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026346/0000899243-19-026346-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004509/0000899243-20-004509-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004511/0000899243-20-004511-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006864/0000899243-20-006864-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006865/0000899243-20-006865-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006867/0000899243-20-006867-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320025326/0000899243-20-025326-index.htm
2020-07-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000090266420002724/0000902664-20-002724-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963819000988/0000929638-19-000988-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963820000331/0000929638-20-000331-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919056233/0001104659-19-056233-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919057348/0001104659-19-057348-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-11-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1759138/000110465919061822/0001104659-19-061822-index.htm
2019-10-24S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519273939/0001193125-19-273939-index.htm
2019-10-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519274807/0001193125-19-274807-index.htm
2019-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519277804/0001193125-19-277804-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312519278927/0001193125-19-278927-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519287367/0001193125-19-287367-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520005110/0001193125-20-005110-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520017724/0001193125-20-017724-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520038349/0001193125-20-038349-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520042689/0001193125-20-042689-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520090013/0001193125-20-090013-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520091086/0001193125-20-091086-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520115863/0001193125-20-115863-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520134391/0001193125-20-134391-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520139782/0001193125-20-139782-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/0001193125-20-153792-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520211336/0001193125-20-211336-index.htm
2019-10-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001374/0001193805-19-001374-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380520000185/0001193805-20-000185-index.htm
2019-12-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459019045375/0001564590-19-045375-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/0001564590-20-013929-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020024508/0001564590-20-024508-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/0001564590-20-037278-index.htm
2019-10-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1759138/999999999519002384/9999999995-19-002384-index.htm

Cabaletta Bio, Inc (CABA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cabaletta Bio, Inc (CABA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 523%
Institutional Ownership: 6740%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-295AM Ventures V, L.P.10% Share HolderBuy454,545.0011.004,999,995.00454,545.00https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-10-29James E Flynn10% Share HolderBuy700,000.0011.007,700,000.00700,000.00https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm